Phase I/Ib study of crenolanib with ramucirumab and paclitaxel as second-line therapy for advanced esophagogastric adenocarcinoma

Purpose Paclitaxel plus ramucirumab is a standard second-line regimen for patients with advanced gastric adenocarcinoma, but clinical benefit remains modest. One potential resistance mechanism to VEGFR2 inhibition is activation of the PDGF/PDGFR pathway, which can be blocked by the selective inhibit...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer chemotherapy and pharmacology Jg. 89; H. 2; S. 255 - 265
Hauptverfasser:	Moy, Ryan H., Greally, Megan, Chou, Joanne F., Li, Jia, Desai, Avni M., Chalasani, Sree B., Won, Elizabeth, Kelsen, David P., Ilson, David H., Janjigian, Yelena Y., Capanu, Marinela, Ku, Geoffrey Y.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Berlin/Heidelberg Springer Berlin Heidelberg 01.02.2022 Springer Nature B.V
Schlagworte:	Adenocarcinoma Adenocarcinoma - drug therapy Adenocarcinoma - pathology Adult Aged Antibodies, Monoclonal, Humanized - administration & dosage Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - pharmacology Benzimidazoles - administration & dosage Cancer Cancer Research Clinical Trial Report Dose-Response Relationship, Drug Esophageal cancer Esophageal Neoplasms - drug therapy Esophageal Neoplasms - pathology Female Gastric cancer Humans Immunotherapy Leukopenia Male Maximum Tolerated Dose Medicine Medicine & Public Health Metastases Middle Aged Monoclonal antibodies Neutropenia Oncology Paclitaxel Paclitaxel - administration & dosage Patients Pharmacology/Toxicology Piperidines - administration & dosage Platelet-derived growth factor Progression-Free Survival Ramucirumab Stomach Neoplasms - drug therapy Stomach Neoplasms - pathology Targeted cancer therapy VEGFR2 PDGFR Ramucirumab Crenolanib Gastric cancer Esophageal cancer
ISSN:	0344-5704, 1432-0843, 1432-0843
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!